Cardiff Oncology Inc: Why Investors Shouldn’t Get Rid Of CRDF Stock In 2025
In the last trading session, 2.12 million shares of the Cardiff Oncology Inc (NASDAQ:CRDF) were traded, and its beta was 1.56. Most recently the company’s
In the last trading session, 2.12 million shares of the Cardiff Oncology Inc (NASDAQ:CRDF) were traded, and its beta was 1.56. Most recently the company’s
Cardiff Oncology Inc (NASDAQ:CRDF)’s traded shares stood at 0.64 million during the last session, with the company’s beta value hitting 1.56. At the close of
In the last trading session, 1.04 million Cardiff Oncology Inc (NASDAQ:CRDF) shares changed hands as the company’s beta touched 1.52. With the company’s per share
In last trading session, Cardiff Oncology Inc (NASDAQ:CRDF) saw 1.55 million shares changing hands with its beta currently measuring 1.55. Company’s recent per share price
Cardiff Oncology Inc (NASDAQ:CRDF) has a beta value of 68.48% and has seen 1.2 shares traded in the last trading session. The company, currently valued
In today’s recent session, 1.34 million shares of the Cardiff Oncology Inc (NASDAQ:CRDF) have been traded, and its beta is 1.56. Most recently the company’s
Cardiff Oncology Inc (NASDAQ:CRDF) has a beta value of 1.56 and has seen 0.45 million shares traded in the recent trading session. The company, currently
© 2024, Powered by Smart TechOne